SG11201709782SA - Xanthine derivative - Google Patents

Xanthine derivative

Info

Publication number
SG11201709782SA
SG11201709782SA SG11201709782SA SG11201709782SA SG11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA SG 11201709782S A SG11201709782S A SG 11201709782SA
Authority
SG
Singapore
Prior art keywords
xanthine derivative
xanthine
derivative
Prior art date
Application number
SG11201709782SA
Other languages
English (en)
Inventor
Yuzhe Gao
Guocheng Wang
Original Assignee
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Tasly Diyi Pharmaceutical Co Ltd filed Critical Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Publication of SG11201709782SA publication Critical patent/SG11201709782SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201709782SA 2015-05-29 2016-05-26 Xanthine derivative SG11201709782SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510290336 2015-05-29
PCT/CN2016/083406 WO2016192559A1 (zh) 2015-05-29 2016-05-26 黄嘌呤衍生物

Publications (1)

Publication Number Publication Date
SG11201709782SA true SG11201709782SA (en) 2017-12-28

Family

ID=57440191

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201709782SA SG11201709782SA (en) 2015-05-29 2016-05-26 Xanthine derivative

Country Status (15)

Country Link
US (1) US10358449B2 (ru)
EP (1) EP3305787B1 (ru)
JP (1) JP6742345B2 (ru)
KR (1) KR20180011270A (ru)
CN (2) CN106188058B (ru)
AU (1) AU2016270100B2 (ru)
CA (1) CA2987697A1 (ru)
ES (1) ES2908658T3 (ru)
HK (1) HK1245796A1 (ru)
IL (1) IL255829B (ru)
MY (1) MY186396A (ru)
RU (1) RU2709348C2 (ru)
SG (1) SG11201709782SA (ru)
TW (1) TWI682931B (ru)
WO (1) WO2016192559A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105983016B (zh) 2015-03-23 2023-08-11 天士力医药集团股份有限公司 一种含有水飞蓟宾的药物组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2003057200A2 (en) * 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE102004008112A1 (de) * 2004-02-18 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN102199151A (zh) * 2004-02-18 2011-09-28 贝林格尔.英格海姆国际有限公司 8-[3-氨基-哌啶-1-基]-黄嘌呤、制备及用途
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) * 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
CN103172633B (zh) * 2011-12-22 2016-08-03 成都地奥制药集团有限公司 一种化合物及其制备方法和用途

Also Published As

Publication number Publication date
EP3305787A1 (en) 2018-04-11
AU2016270100A1 (en) 2017-12-14
IL255829B (en) 2021-02-28
CN107709324B (zh) 2021-06-08
US10358449B2 (en) 2019-07-23
EP3305787A4 (en) 2018-11-21
CN106188058A (zh) 2016-12-07
RU2709348C2 (ru) 2019-12-18
TWI682931B (zh) 2020-01-21
HK1245796A1 (zh) 2018-08-31
TW201643166A (zh) 2016-12-16
KR20180011270A (ko) 2018-01-31
RU2017145919A3 (ru) 2019-08-09
US20180162860A1 (en) 2018-06-14
AU2016270100B2 (en) 2020-02-13
EP3305787B1 (en) 2022-02-16
WO2016192559A1 (zh) 2016-12-08
IL255829A (en) 2018-01-31
JP6742345B2 (ja) 2020-08-19
JP2018520120A (ja) 2018-07-26
MY186396A (en) 2021-07-22
RU2017145919A (ru) 2019-07-02
CA2987697A1 (en) 2016-12-08
CN106188058B (zh) 2020-11-06
CN107709324A (zh) 2018-02-16
ES2908658T3 (es) 2022-05-03

Similar Documents

Publication Publication Date Title
HK1255045A1 (zh) 取代的氧代吡啶衍生物
IL253381B (en) History of h9–pyrrolo–dipyridine
IL252777B (en) A dihydroindolizinone derivative
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3131898T3 (pl) Pochodne fluoroalkilofluorenu
PL3418273T3 (pl) Pochodne flawaglin
IL248773A0 (en) History of naphthyridinedione
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
IL251005B (en) Pyrido-oxazinone derivatives
SG10201913525QA (en) Pyrimidine derivative
IL248772A0 (en) A consequence of cyclohexyl pyridine
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
HK1245796A1 (zh) 黃嘌呤衍生物
HK1259107A1 (zh) 氨基唑衍生物